Novartis AG (NVS)
After hours:
| Previous Close | 95.12 |
| Open | 98.74 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 800 |
| Day's Range | 97.03 - 99.50 |
| 52 Week Range | 92.19 - 108.78 |
| Volume | |
| Avg. Volume | 1,578,035 |
| Market Cap | 198.949B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 23.73 |
| EPS (TTM) | 4.10 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.78 (3.88%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | 112.57 |
- Yahoo Finance Video
Novartis raises full-year guidance on Q1 beat, drug sales
Shares of Novartis (NVS) are soaring in Tuesday's pre-market trading session — holding onto steady gains into the market open — after the Swiss pharmaceutical giant reported better-than-expected first-quarter earnings and raised its full-year guidance. The robust financial performance was driven primarily by strong sales of the company's innovative heart failure and psoriasis treatment drugs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
GlobeNewswireNovartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem
Investor's Business DailyHow Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint
Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.
